Search Results

With more than $1.5 billion on the line, Gilead looks to bolster its CAR T portfolio.

● CANDID-CNS™ is the new state-of-the-art AI model for BBB penetration: it achieves 87% AUPRC on bRo5 small molecules compared to 56% by Pfizer’s CNS MPO. ● CANDID-CNS™ distinguishes CNS penetrant stereoisomers at 68% compared to 50% by Pfizer’s CNS MPO. ● Published in the Journal of Chemical Information and Modeling, CANDID-CNS™ presents a breakthrough in AI Drug Discovery by unlocking the potential of bRo5 and stereochemistry to significantly expand the chemical space of small molecules that can be developed into CNS therapeutics.

As 2026 begins, a slate of high-stakes clinical readouts—from a pivotal study of Novartis’ cardiovascular candidate pelacarsen to a Phase III test of Eli Lilly’s next-gen Alzheimer’s drug—are poised to reshape therapeutic landscapes.

The R&D pipeline for depression therapies faced a demoralizing 2025 as five high-profile candidates, including KOR antagonists by Johnson & Johnson and Neumora Therapeutics, flunked late-stage clinical trials, underscoring the persistent challenges of CNS drug development.

In the midst of regulatory and political upheaval, biopharma’s R&D engine kept running, churning out highs and lows in equal parts. Here are some of this year’s most glorious clinical trial victories.

Every year in biopharma brings its share of grueling defeats, and 2025 was no different, especially for companies targeting neurological diseases. Some failures split up partners, and one particularly egregious case even led to the demise of an entire company.

Pfizer and Metsera, Sarepta and uniQure made the list with dramatic tales. The other two spots went to the regulatory challenges facing biopharma under the new administration, especially in the vaccines sector.